Search Within

Madhulika Shukla

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Adult Leukemia (6)
  2. Center for Hematologic Malignancies (6)
  3. Department of Medicine (6)
  4. Hematologic Malignancies, Division of (6)
  5. Executive Committee, Center for Hematologic Malignancies (4)
  6. GSK Faculty (4)

More Groups

People
  1. Jae Park (6)
  2. Martin Tallman (5)
  3. Shreya Vemuri (5)
  4. Omar Abdel-Wahab (4)
  5. Jose Salcedo (2)
  6. Julie Kinoshita (2)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (2)
  4. 2019 (1)
Publications
  1. Blood (4)
  2. Haematologica (1)
  3. NEJM Evidence (1)
Publishers
  1. American Society of Hematology (4)
  2. Ferrata Storti Foundation (1)
  3. Massachusetts Medical Society (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: Results of a phase I trial
    Meeting Abstract

    Valtis, Y. K.; Geyer, M. B.; Torres, M.; Grogan, M.; Shukla, M.; Stein, E. M.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Journal Article

    Handa, S.; Lee, J. O.; Derkach, A.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Shukla, M.; Vemuri, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Journal Article

    Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Vemuri, S.; Flynn, J.; Hsu, M.; Devlin, S. M.; Roshal, M.; Gao, Q.; Shukla, M.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save